Chr. Hansen Holding — M&A Activity 2019

Apr 2, 2019

Chr. Hansen and Lonza establish a 50/50 joint venture to pioneer the emerging market for live biotherapeutic products

Chr. Hansen and Lonza establish a 50/50 joint venture to pioneer the emerging market for live biotherapeutic products

Company Announcement No. 4/2019

Announcement attached below

For further information, please contact:

Head of Investor Relations

Martin Riise

Tel.: +45 5339 2250 

Investor Relations Officer

Annika Stern

Tel.: +45 2399 2382

Head of Media Relations

Camilla Lercke

Tel.: +45 5339 2384

Attachment

• No 04 2019 Company announcement joint venture